Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
作者： R. K. Jain
关键词: Vascular endothelial growth factor A 、 Immunotherapy 、 Neovascularization 、 Cancer 、 Antiangiogenesis Therapy 、 Regenerative medicine 、 Bevacizumab 、 Combined Modality Therapy 、 Medicine 、 Cancer research
摘要: Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic should destroy vasculature, thereby depriving of oxygen nutrients. Here, I review emerging evidence supporting an alternative hypothesis-that certain agents can also transiently "normalize" abnormal structure function vasculature to make it more efficient drug delivery. Drugs induce vascular normalization alleviate hypoxia increase efficacy conventional if both carefully scheduled. A better understanding molecular cellular underpinnings may ultimately lead effective not only but diseases with as well regenerative medicine, in which goal create maintain a functionally normal
sciencemag.org
harvard.edu
unirioja.es参考文章(53)
Timothy P. Padera, Dai Fukumura, Ananth Kadambi, Peter Carmeliet, Dennis E. J. G. J. Dolmans, Rakesh K. Jain, Chae-ok Yun, Carla Mouta Carreira, Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Research. ,vol. 61, pp. 2404- 2408 ,(2001)
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
K. Hellmann, Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. Clinical & Experimental Metastasis. ,vol. 20, pp. 95- 102 ,(2003) , 10.1023/A:1022632413888
Herman D. Suit, Genevièeve Griffon-Etienne, Christian Brekken, Yves Boucher, Rakesh K. Jain, Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Research. ,vol. 59, pp. 3776- 3782 ,(1999)
Peter Carmeliet, Rakesh K. Jain, Angiogenesis in cancer and other diseases Nature. ,vol. 407, pp. 249- 257 ,(2000) , 10.1038/35025220
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
Susan LeJeune, Russell Leek, Stephen Fox, Ruth Whitehouse, Amir Moghaddam, Prudence A. E. Scott, Roy Bicknell, Micheie Relf, Kenneth Smith, Adrian L. Harris, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research. ,vol. 57, pp. 963- 969 ,(1997)
Paul Perrotte, Hiroki Kuniyasu, Beryl Y. Eve, Daniel J. Hicklin, Keiji Inoue, Colin P. N. Dinney, Robert Radinsky, Takashi Matsumoto, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research. ,vol. 5, pp. 257- 265 ,(1999)
Donald P. Bottaro, Lance A. Liotta, Cancer: Out of air is not out of action. Nature. ,vol. 423, pp. 593- 595 ,(2003) , 10.1038/423593A
Ricky T. Tong, Yves Boucher, Sergey V. Kozin, Frank Winkler, Daniel J. Hicklin, Rakesh K. Jain, Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors Cancer Research. ,vol. 64, pp. 3731- 3736 ,(2004) , 10.1158/0008-5472.CAN-04-0074